Christine Maurer

Ms. Maurer is senior vice president of development operations and regulatory affairs at Autobahn Therapeutics

Ms. Maurer brings substantial senior leadership experience in the management of multi-million-dollar R&D portfolio programs in the life sciences industry. Most recently, Ms. Maurer was senior vice president, program management at Kiniksa Pharmaceuticals where she served as a key contributor in building a start-up company with an advancing pipeline of four clinical stage assets focused in rare autoinflammatory and autoimmune disease areas. Prior to Kiniksa, Ms. Maurer was vice president of business operations at Synageva BioPharma, where she led the company sponsored study to accelerate the widespread screening and identification of patients with LAL Deficiency (an ultrarare disease) in 100+ centers globally in preparation for BLA approval and commercial launch of Kanuma™.  Prior to that role, Christine served as vice president of program management and operations and led the Kanuma™ program for LAL Deficiency to successful IND/CTA filings, completion of a global Phase 1/2 trial and initiation of the pivotal Phase 3 ARISE trial and was a key contributor to building the rare disease product portfolio. Prior to Synageva, Christine held roles of increasing responsibility in project, program & alliance management at Biogen Idec, Molecular Insight Pharma (Progenics), Globomax (ICON) and US Surgical Corporation (Medtronic). She also served as a project management consultant for Integrated Project Management Corporation. Ms. Maurer holds a B.A. in business administration from Pace University in New York and an M.S. in project and program management from Brandeis University in Massachusetts.